MSB Trading 2022, The TurnAround, page-496

Wow. Now that’s what I call being …. Ahhhhhhhhh … optimistic.

Let’s just unpack that a bit.

So, a licence agreement for an unapproved unproven application years away (at best). You’re sure to get more for a dog licence. Oh, the debt facilities have been fully drawn except for the final $30 million. But hang on there, there are still conditions (those dreaded msb “closing conditions”) so it’s very unlikely that those funds will be available.

Cash spend is reducing because trials are not permitted until the potency issues are resolved. Income from Japan would be lucky to amount to interest on all the debt.

So, all msb needs is to get approval and then big pharma will be knocking. Well, that sounds pretty good for big pharma … no risk there. No one knocking today but.

Get your eyes checked loopy ..